Abbott Laboratories (ABT) Stock Forecast, Price Target & Predictions
ABT Stock Forecast
Abbott Laboratories stock forecast is as follows: an average price target of $129.50 (represents a 13.74% upside from ABT’s last price of $113.86) and a rating consensus of 'Buy', based on 14 wall street analysts offering a 1-year stock forecast.
ABT Price Target
The average price target for Abbott Laboratories (ABT) is $129.50 based on 1-year price targets from 14 Wall Street analysts in the past 3 months, with a price target range of $150.00 to $117.49. This represents a potential 13.74% upside from ABT's last price of $113.86.
ABT Analyst Ratings
According to 14 Wall Street analysts, Abbott Laboratories's rating consensus is 'Buy'. The analyst rating breakdown for ABT stock is 0 'Strong Buy' (0.00%), 11 'Buy' (78.57%), 3 'Hold' (21.43%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Abbott Laboratories Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 27, 2024 | Matthew Taylor | Jefferies | $120.00 | $112.22 | 6.93% | 5.39% |
| Aug 22, 2024 | Joanne Wuensch | Citigroup | $127.00 | $111.39 | 14.01% | 11.54% |
| Jul 18, 2024 | Jayson Bedford | Raymond James | $127.00 | $104.68 | 21.32% | 11.54% |
| Jul 18, 2024 | Joanna Wiensch | Citigroup | $119.00 | $104.68 | 13.68% | 4.51% |
| Jul 02, 2024 | Vijay Kumar | Evercore ISI | $120.00 | $103.20 | 16.28% | 5.39% |
| Jun 03, 2024 | Marie Thibault | BTIG | $135.00 | $102.99 | 31.08% | 18.57% |
| May 30, 2024 | David Roman | Goldman Sachs | $121.00 | $100.73 | 20.12% | 6.27% |
| Apr 22, 2024 | Matt Miksic | Barclays | $140.00 | $107.07 | 30.76% | 22.96% |
| Apr 18, 2024 | Lee Hambright | Bernstein | $133.00 | $105.27 | 26.34% | 16.81% |
| Apr 18, 2024 | Shagun Singh | RBC Capital | $125.00 | $105.90 | 18.04% | 9.78% |
The latest Abbott Laboratories stock forecast, released on Aug 27, 2024 by Matthew Taylor from Jefferies, set a price target of $120.00, which represents a 6.93% increase from the stock price at the time of the forecast ($112.22), and a 5.39% increase from ABT last price ($113.86).
Abbott Laboratories Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 5 | 10 |
| Avg Price Target | $123.50 | $122.60 | $126.70 |
| Last Closing Price | $113.86 | $113.86 | $113.86 |
| Upside/Downside | 8.47% | 7.68% | 11.28% |
In the current month, the average price target of Abbott Laboratories stock is $123.50, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 8.47% increase as opposed to Abbott Laboratories's last price of $113.86. This month's average price target is up 0.73% compared to last quarter, and down -2.53% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 05, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 27, 2024 | Jefferies | Hold | Hold | Hold |
| Aug 22, 2024 | RBC Capital | Buy | Buy | Hold |
| Aug 22, 2024 | Goldman Sachs | Underperform | Underperform | Hold |
| Aug 21, 2024 | Citigroup | Buy | Buy | Hold |
| Jul 29, 2024 | Edward Jones | - | Hold | Downgrade |
| Jul 18, 2024 | Citigroup | Buy | Buy | Hold |
| Jul 18, 2024 | Raymond James | Outperform | Outperform | Hold |
| Jul 18, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Jul 18, 2024 | Barclays | Overweight | Overweight | Hold |
Abbott Laboratories's last stock rating was published by Cowen & Co. on Sep 05, 2024. The company gave ABT a "Buy" rating, the same as its previous rate.
Abbott Laboratories Financial Forecast
Abbott Laboratories Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $10.24B | $10.14B | $9.98B | $9.75B | $10.09B | $10.41B | - | $11.89B | $11.47B | $10.93B | $10.22B | $10.46B | $10.70B | $8.85B | $7.33B | $7.73B | $8.31B | $8.08B |
| Avg Forecast | $12.57B | $12.21B | $11.99B | $11.47B | $11.72B | $11.33B | $11.15B | $10.66B | $10.86B | $10.53B | $10.37B | $9.88B | $10.19B | $9.84B | $9.71B | $9.67B | $9.66B | $9.65B | $10.33B | $11.00B | $10.71B | $9.56B | $9.69B | $10.69B | $9.94B | $8.54B | $6.81B | $7.44B | $8.27B | $8.11B |
| High Forecast | $12.72B | $12.36B | $12.14B | $11.60B | $11.86B | $11.46B | $11.28B | $10.79B | $10.98B | $10.55B | $10.49B | $10.00B | $10.37B | $9.96B | $9.83B | $9.78B | $9.78B | $9.76B | $10.33B | $11.17B | $10.88B | $9.72B | $9.84B | $10.86B | $10.09B | $8.67B | $6.92B | $7.56B | $8.40B | $8.23B |
| Low Forecast | $12.44B | $12.08B | $11.87B | $11.35B | $11.59B | $11.21B | $11.03B | $10.55B | $10.74B | $10.51B | $10.26B | $9.78B | $10.07B | $9.74B | $9.61B | $9.56B | $9.56B | $9.55B | $10.33B | $10.88B | $10.59B | $9.46B | $9.58B | $10.57B | $9.83B | $8.45B | $6.73B | $7.36B | $8.18B | $8.02B |
| # Analysts | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 10 | 11 | 5 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 8 | 10 | 14 | 8 | 8 | 10 | 13 | 7 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | 1.03% | 1.03% | 1.01% | 1.04% | 1.08% | - | 1.08% | 1.07% | 1.14% | 1.06% | 0.98% | 1.08% | 1.04% | 1.08% | 1.04% | 1.01% | 1.00% |
Abbott Laboratories's average Quarter revenue forecast for Mar 24 based on 10 analysts is $9.88B, with a low forecast of $9.78B, and a high forecast of $10.00B. ABT's average Quarter revenue forecast represents a -3.49% decrease compared to the company's last Quarter revenue of $10.24B (Dec 23).
Abbott Laboratories EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 10 | 11 | 5 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 8 | 10 | 14 | 8 | 8 | 10 | 13 | 7 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $2.66B | $2.23B | $2.22B | $2.11B | $1.87B | $2.36B | - | $3.50B | $3.34B | $3.47B | $2.36B | $3.11B | $3.39B | $2.37B | $1.49B | $1.62B | $2.16B | $2.02B |
| Avg Forecast | $2.98B | $2.90B | $2.85B | $2.72B | $2.78B | $2.69B | $2.65B | $2.53B | $2.58B | $2.50B | $2.46B | $3.81B | $2.42B | $2.34B | $2.30B | $3.47B | $2.29B | $2.21B | $2.45B | $3.15B | $3.04B | $2.01B | $1.98B | $2.99B | $3.14B | $2.18B | $954.64M | $1.42B | $2.16B | $2.02B |
| High Forecast | $3.02B | $2.93B | $2.88B | $2.75B | $2.81B | $2.72B | $2.68B | $2.56B | $2.61B | $2.50B | $2.49B | $4.58B | $2.46B | $2.36B | $2.33B | $4.16B | $2.32B | $2.65B | $2.45B | $3.78B | $3.64B | $2.41B | $2.38B | $3.59B | $3.77B | $2.62B | $1.15B | $1.71B | $2.59B | $2.43B |
| Low Forecast | $2.95B | $2.87B | $2.82B | $2.69B | $2.75B | $2.66B | $2.62B | $2.50B | $2.55B | $2.50B | $2.43B | $3.05B | $2.39B | $2.31B | $2.28B | $2.77B | $2.27B | $1.77B | $2.45B | $2.52B | $2.43B | $1.61B | $1.59B | $2.39B | $2.51B | $1.75B | $763.71M | $1.14B | $1.73B | $1.62B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.10% | 0.95% | 0.96% | 0.61% | 0.81% | 1.07% | - | 1.11% | 1.10% | 1.73% | 1.19% | 1.04% | 1.08% | 1.08% | 1.56% | 1.14% | 1.00% | 1.00% |
10 analysts predict ABT's average Quarter EBITDA for Mar 24 to be $3.81B, with a high of $4.58B and a low of $3.05B. This is 43.19% upper than Abbott Laboratories's previous annual EBITDA (Dec 23) of $2.66B.
Abbott Laboratories Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 10 | 11 | 5 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 8 | 10 | 14 | 8 | 8 | 10 | 13 | 7 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $1.59B | $1.44B | $1.38B | $1.32B | $1.03B | $1.44B | - | $2.45B | $1.99B | $2.10B | $1.19B | $1.79B | $2.16B | $1.23B | $537.00M | $564.00M | $1.05B | $960.00M |
| Avg Forecast | $2.71B | $2.55B | $2.48B | $2.22B | $2.53B | $2.33B | $2.22B | $1.96B | $2.34B | $2.10B | $1.93B | $2.44B | $2.08B | $1.93B | $1.84B | $2.22B | $1.62B | $1.34B | $1.97B | $2.01B | $1.81B | $1.22B | $1.00B | $1.72B | $2.00B | $1.14B | $345.21M | $495.93M | $1.05B | $960.00M |
| High Forecast | $2.75B | $2.59B | $2.52B | $2.26B | $2.57B | $2.36B | $2.25B | $1.99B | $2.38B | $2.14B | $1.96B | $2.92B | $2.12B | $1.96B | $1.87B | $2.66B | $1.65B | $1.60B | $1.97B | $2.42B | $2.17B | $1.46B | $1.20B | $2.07B | $2.40B | $1.36B | $414.26M | $595.12M | $1.26B | $1.15B |
| Low Forecast | $2.67B | $2.52B | $2.45B | $2.19B | $2.49B | $2.29B | $2.19B | $1.93B | $2.31B | $2.07B | $1.91B | $1.95B | $2.07B | $1.90B | $1.81B | $1.77B | $1.60B | $1.07B | $1.97B | $1.61B | $1.45B | $972.63M | $800.51M | $1.38B | $1.60B | $909.78M | $276.17M | $396.74M | $839.20M | $768.00M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.77% | 0.75% | 0.75% | 0.59% | 0.64% | 1.07% | - | 1.21% | 1.10% | 1.73% | 1.19% | 1.04% | 1.08% | 1.08% | 1.56% | 1.14% | 1.00% | 1.00% |
Abbott Laboratories's average Quarter net income forecast for Mar 24 is $2.44B, with a range of $1.95B to $2.92B. ABT's average Quarter net income forecast represents a 52.90% increase compared to the company's last Quarter net income of $1.59B (Dec 23).
Abbott Laboratories SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 10 | 11 | 5 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 8 | 10 | 14 | 8 | 8 | 10 | 13 | 7 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $2.70B | $2.72B | $2.74B | $2.76B | $2.97B | $2.73B | - | $2.79B | $3.05B | $2.77B | $2.73B | $2.78B | $2.57B | $2.30B | $2.28B | $2.55B | $2.41B | $2.44B |
| Avg Forecast | $3.47B | $3.37B | $3.31B | $3.16B | $3.23B | $3.13B | $3.08B | $2.94B | $3.00B | $2.91B | $2.86B | $2.78B | $2.81B | $2.72B | $2.68B | $2.52B | $2.67B | $1.76B | $2.85B | $2.29B | $2.77B | $1.60B | $2.29B | $2.67B | $2.38B | $2.12B | $1.46B | $2.24B | $2.41B | $2.44B |
| High Forecast | $3.51B | $3.41B | $3.35B | $3.20B | $3.27B | $3.16B | $3.11B | $2.98B | $3.03B | $2.91B | $2.90B | $3.33B | $2.86B | $2.75B | $2.71B | $3.03B | $2.70B | $2.11B | $2.85B | $2.75B | $3.33B | $1.92B | $2.75B | $3.21B | $2.86B | $2.55B | $1.76B | $2.69B | $2.90B | $2.93B |
| Low Forecast | $3.43B | $3.33B | $3.27B | $3.13B | $3.20B | $3.09B | $3.04B | $2.91B | $2.96B | $2.90B | $2.83B | $2.22B | $2.78B | $2.69B | $2.65B | $2.02B | $2.64B | $1.41B | $2.85B | $1.84B | $2.22B | $1.28B | $1.84B | $2.14B | $1.90B | $1.70B | $1.17B | $1.79B | $1.93B | $1.95B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.96% | 1.00% | 1.02% | 1.09% | 1.11% | 1.55% | - | 1.21% | 1.10% | 1.73% | 1.19% | 1.04% | 1.08% | 1.08% | 1.56% | 1.14% | 1.00% | 1.00% |
Abbott Laboratories's average Quarter SG&A projection for Mar 24 is $2.78B, based on 10 Wall Street analysts, with a range of $2.22B to $3.33B. The forecast indicates a 2.66% rise compared to ABT last annual SG&A of $2.70B (Dec 23).
Abbott Laboratories EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 10 | 11 | 5 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 8 | 10 | 14 | 8 | 8 | 10 | 13 | 7 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $0.91 | $0.83 | $0.79 | $0.76 | $0.59 | $1.15 | - | $1.40 | $1.13 | $1.19 | $0.67 | $1.01 | $1.22 | $0.70 | $0.30 | $0.32 | $0.60 | $0.54 |
| Avg Forecast | $1.55 | $1.46 | $1.42 | $1.27 | $1.44 | $1.33 | $1.27 | $1.12 | $1.34 | $1.20 | $1.10 | $0.95 | $1.19 | $1.10 | $1.05 | $0.99 | $0.93 | $0.94 | $1.13 | $1.47 | $1.21 | $0.94 | $1.02 | $1.27 | $1.35 | $0.91 | $0.42 | $0.59 | $0.95 | $0.84 |
| High Forecast | $1.57 | $1.48 | $1.44 | $1.29 | $1.46 | $1.35 | $1.29 | $1.14 | $1.36 | $1.22 | $1.12 | $0.97 | $1.21 | $1.12 | $1.07 | $1.01 | $0.94 | $0.96 | $1.13 | $1.50 | $1.23 | $0.96 | $1.04 | $1.30 | $1.38 | $0.93 | $0.43 | $0.60 | $0.97 | $0.86 |
| Low Forecast | $1.53 | $1.44 | $1.40 | $1.25 | $1.42 | $1.31 | $1.25 | $1.10 | $1.32 | $1.18 | $1.09 | $0.94 | $1.18 | $1.09 | $1.04 | $0.98 | $0.91 | $0.93 | $1.13 | $1.44 | $1.19 | $0.93 | $1.00 | $1.26 | $1.33 | $0.90 | $0.41 | $0.58 | $0.93 | $0.83 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.76% | 0.75% | 0.75% | 0.77% | 0.64% | 1.22% | - | 0.96% | 0.94% | 1.26% | 0.66% | 0.79% | 0.90% | 0.77% | 0.73% | 0.54% | 0.63% | 0.65% |
According to 10 Wall Street analysts, Abbott Laboratories's projected average Quarter EPS for Mar 24 is $0.95, with a low estimate of $0.94 and a high estimate of $0.97. This represents a 4.95% increase compared to ABT previous annual EPS of $0.91 (Dec 23).
Abbott Laboratories Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | $48.70 | $65.43 | 34.35% | Hold |
| MDT | Medtronic | $89.89 | $106.77 | 18.78% | Buy |
| ABT | Abbott Laboratories | $113.86 | $129.50 | 13.74% | Buy |
| JNJ | Johnson & Johnson | $164.38 | $176.29 | 7.25% | Buy |
| ABBV | AbbVie | $193.40 | $167.54 | -13.37% | Buy |
| LLY | Eli Lilly and Company | $902.71 | $734.40 | -18.64% | Buy |
ABT Forecast FAQ
Is Abbott Laboratories a good buy?
Yes, according to 14 Wall Street analysts, Abbott Laboratories (ABT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 11 'Buy' recommendations, accounting for 78.57% of ABT's total ratings.
What is ABT's price target?
Abbott Laboratories (ABT) average price target is $129.5 with a range of $117.49 to $150, implying a 13.74% from its last price of $113.86. The data is based on 14 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Abbott Laboratories stock go up soon?
According to Wall Street analysts' prediction for ABT stock, the company can go up by 13.74% (from the last price of $113.86 to the average price target of $129.5), up by 31.74% based on the highest stock price target, and up by 3.19% based on the lowest stock price target.
Can Abbott Laboratories stock reach $200?
ABT's average twelve months analyst stock price target of $129.5 does not support the claim that Abbott Laboratories can reach $200 in the near future.
What is Abbott Laboratories's current price target trend?
2 Wall Street analysts forecast a $123.5 price target for Abbott Laboratories (ABT) this month, up 8.47% from its last price of $113.86. Compared to the last 3 and 12 months, the average price target increased by 7.68% and increased by 11.28%, respectively.
What are Abbott Laboratories's analysts' financial forecasts?
Abbott Laboratories's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $44.86B (high $45.39B, low $44.38B), average EBITDA is $10.65B (high $10.77B, low $10.53B), average net income is $9.03B (high $9.17B, low $8.9B), average SG&A $12.38B (high $12.53B, low $12.25B), and average EPS is $5.16 (high $5.23, low $5.08). ABT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $48.25B (high $48.82B, low $47.74B), average EBITDA is $11.45B (high $11.59B, low $11.33B), average net income is $9.97B (high $10.12B, low $9.83B), average SG&A $13.31B (high $13.47B, low $13.17B), and average EPS is $5.69 (high $5.78, low $5.61).
Did the ABT's actual financial results beat the analysts' financial forecasts?
Based on Abbott Laboratories's last annual report (Dec 2023), the company's revenue was $40.11B, beating the average analysts forecast of $39.4B by 1.79%. Apple's EBITDA was $9.93B, missing the average prediction of $10.52B by -5.62%. The company's net income was $5.72B, missing the average estimation of $8.06B by -29.03%. Apple's SG&A was $10.86B, beating the average forecast of $10.73B by 1.20%. Lastly, the company's EPS was $3.26, missing the average prediction of $4.33 by -24.72%. In terms of the last quarterly report (Dec 2023), Abbott Laboratories's revenue was $10.24B, beating the average analysts' forecast of $10.19B by 0.54%. The company's EBITDA was $2.66B, beating the average prediction of $2.42B by 10.21%. Abbott Laboratories's net income was $1.59B, missing the average estimation of $2.08B by -23.47%. The company's SG&A was $2.7B, missing the average forecast of $2.81B by -3.80%. Lastly, the company's EPS was $0.91, missing the average prediction of $1.19 by -23.50%